SEARCH

SEARCH BY CITATION

References

  • 1
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). JAMA 2001;285:24862497.
  • 2
    Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DRJ, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective american studies. Circulation 1989;79:815.
  • 3
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The framingham study. Am J Med 1977;62:707714.
  • 4
    Genest JJ, McNamara JR, Salem DN, Schaefer EJ. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:11851189.
  • 5
    Sanossian N, Saver JL, Navab M, Ovbiagele B. High-density lipoprotein cholesterol: An emerging target for stroke treatment. Stroke 2007;38:11041109.
  • 6
    Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007;356:13041316.
  • 7
    Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002;144:165172.
  • 8
    Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27:68S-71.
  • 9
    Gotto AM, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: A working group report and update. J Am Coll Cardiol 2004;43:717724.
  • 10
    Brewer HB, Jr. Increasing HDL cholesterol levels. N Engl J Med 2004;350:14911494.
  • 11
    Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med 2005;353:12521260.
  • 12
    Flemming RM. The effect of high-, moderate-, and low-fat diets on weight loss and cardiovascualr disease risk factors. Prev Cardiol 2002;5:110118.
  • 13
    Williams PT. The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism 2004;53:700709.
  • 14
    Bloomfield HE. The role of fibrates in a statin world. Arch Intern Med 2006;166:715716.
  • 15
    Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:25852590.
  • 16
    Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004;15:659665.
  • 17
    Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (arbiter) 2. Circulation 2004;110:35123517.
  • 18
    Guyton JR, Blazing MA, Hagar J, Kashyap ML, Knopp RH, McKenney JM, Nash DT, Nash SD. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-gemfibrozil study group. Arch Intern Med 2000;160:11771184
  • 19
    Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, Group SS. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (stellar trial). Am J Cardiol 2003;92:152160.
  • 20
    Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif J-C et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The asteroid trial. JAMA 2006;295:15561565.
  • 21
    Sanossian N, Saver JL, Liebeskind DS, Kim D, Razinia T, Ovbiagele B. Achieving target cholesterol goals after stroke: Is hospital initiation the key? Arch Neurol 2006;63:10811083.
  • 22
    Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004;3:271278.
  • 23
    Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:27512756.
  • 24
    Jieli Chen XCAZHJCRCZMLAKCSFMC. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 2007;62:4958.
  • 25
    Paterno RRA, Postiglione A, Hubsch A, Andresen I, Lang MG. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004;17:204211.
  • 26
    Paterno R, Ruocco A, Cicale M, Ferraro P, Baiano A, Spagnuolo G, Ferrara F, Postiglione A. Acute neuroprotective effect of high-density lipoprotein in experimental models of cerebral stroke (abs.). Stroke 2006;37:729.
  • 27
    Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, Brody J. Efficacy and safety of an extended-release niacin (niaspan): A long-term study. Am J Cardiol 1998;82:74U-81U; discussion 85U-86U.
  • 28
    Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA, for the AI. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The admit study: A randomized trial. JAMA 2000;284:12631270.
  • 29
    The coronary drug project research group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360381.
  • 30
    Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986;8:12451255.
  • 31
    Carlson LA, Rosenhamer G. Reduction of mortality in the stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405418.
  • 32
    Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:15831592.
  • 33
    Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM, Jr. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: Effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142:95104.
  • 34
    Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C-R, Liu C-H, Azen SP. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998;128:262269
  • 35
    Pruissen DM, Gerritsen SA, Prinsen TJ, Dijk JM, Kappelle LJ, Algra A. Carotid intima-media thickness is different in large- and small-vessel ischemic stroke: The smart study. Stroke 2007;38:13711373.
  • 36
    Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu CR, Liu CH, Mack WJ, Alaupovic P. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:2028.
  • 37
    Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549559.
  • 38
    Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: Arbiter 3. Curr Med Res Opin 2006;22:22432250.
  • 39
    Devine PJ, Turco MA, Taylor AJ. Design and rationale of the arbiter 6 trial (arterial biology for the investigation of the treatment effects of reducing cholesterol)-6-HDL and LDL treatment strategies in atherosclerosis (halts). Cardiovasc Drugs Ther 2007;21:221225.
  • 40
    Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC et al. Update to the aha/asa recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008;39:16471652.
  • 41
    Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S. Puma-g and hm74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352355.
  • 42
    Tunaru S, Lattig J, Kero J, Krause G, Offermanns S. Characterization of determinants of ligand binding to the nicotinic acid receptor gpr109a (hm74a/puma-g). Mol Pharmacol 2005;68:12711280
  • 43
    Karpe F, Frayn KN. The nicotinic acid receptor—a new mechanism for an old drug. Lancet 2004;363:18921894.
  • 44
    Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apob degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (hepg2) cells. Arterioscler Thromb Vasc Biol 1999;19:10511059.
  • 45
    Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases lp-ai, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol 2001;21:17831789.
  • 46
    Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein a-i but not cholesterol ester by hep g2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:20202028.
  • 47
    Hernandez M, Wright SD, Cai TQ. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 2007;355:10751080.
  • 48
    Zhao SP, Yang J, Li J, Dong SZ, Wu ZH. Effect of niacin on lxralpha and ppargamma expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Int J Cardiol 2008;124:172178.
  • 49
    Tavintharan S, Sivakumar M, Lim SC, Sum CF. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in hepg2 cells. Clin Chim Acta 2007;376:4144.
  • 50
    Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: The copenhagen city heart study. BMJ 1994;309:1115.
  • 51
    Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality: A 21-year follow-up of 8586 men from the israeli ischemic heart disease study. Stroke 1997;28:8387.
  • 52
    Wannamethee SG, Shaper AG, Ebrahim S. Hdl-cholesterol, total cholesterol, and the risk of stroke in middle-aged british men. Stroke 2000;31:18821888.
  • 53
    Simons LA, McCallum J, Friedlander Y, Simons J. Risk factors for ischemic stroke: Dubbo study of the elderly. Stroke 1998;29:13411346.
  • 54
    Curb JD, Abbott RD, Rodriguez BL, Masaki KH, Chen R, Popper JS, Petrovitch H, Ross GW, Schatz IJ, Belleau GC et al. High density lipoprotein cholesterol and the risk of stroke in elderly men: The Honolulu Heart Program. Am J Epidemiol 2004;160:150157.
  • 55
    Shahar E, Chambless LE, Rosamond WD, Boland LL, Ballantyne CM, McGovern PG, Sharrett AR. Plasma lipid profile and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2003;34:623631.
  • 56
    Soyama Y, Miura K, Morikawa Y, Nishijo M, Nakanishi Y, Naruse Y, Kagamimori S, Nakagawa H. High-density lipoprotein cholesterol and risk of stroke in japanese men and women: The oyabe study. Stroke 2003;34:863868.
  • 57
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM, Jr. for the ATRG. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of afcaps/texcaps. JAMA 1998;279:16151622.